Leonard Buckbinder, PhD, is Senior Director Cardiovascular Biology and Acting Head of Cardiovascular Biology. He joined Pfizer in Groton, CT in 1997 and contributed to efforts in cancer, inflammation, osteoporosis and cardiovascular diseases. In inflammation, Dr. Buckbinder conceived and led the identification of dissociated glucocorticoid receptor agonists. Based in Cambridge, MA, he is the research program leader for the myeloperoxidase inhibitor program. Dr. Buckbinder is currently interim leader for Cardiovascular Research, and organized the group into focus areas of vascular inflammation, cardiomyocyte metabolism and function, and the cardiorenal axis. He is also actively involved in working with the External Research and Development Innovation on external research opportunities. Dr. Buckbinder did his graduate work in biochemistry and molecular biology at University of Medicine and Dentistry of New Jersey and Stony Brook University with Dr. Danny Reinberg. He studied RNA polymerase II transcription and how phosphorylation regulates AP1 transcription factors. His postdoctoral work at the Carnegie Institute focused on identification of transcriptional pathways regulated by the thyroid hormone receptor during amphibian metamorphosis. He joined Bristol-Myers Squibb in 1992 and advanced the identification of targets of the p53 tumor suppressor, and first connected oncogenic IGF-1 signaling to p53. This work led to anti-IGF1 programs at Bristol Myers Squibb which were advanced to Ph2.
Clinical data management, Clinical trails, Pharmacovigilance